Nasser Altorki, MD
Thoracic Surgery (Cardiothoracic Vascular Surgery) · New York, NYNPI 1700973898
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $46,078 of the $68,333 with a category attached, or 67.4%. 13 manufacturers reported payments, led by F. Hoffmann-la Roche AG at 35.6% of the total. Reporting peaked in 2023 at $37,788 and has fallen 89.7% since, to $3,890 in 2025. Among thoracic surgery (cardiothoracic vascular surgery) clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 52 payments — averaging $1314.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- F. Hoffmann-la Roche AG$24K
- Regeneron$14K
- Astrazeneca UK Limited$11K
- Merck$6K
- Medtronic$4K
- AstraZeneca$4K
- plus $5K from 7 others
Across 43 payments — averaging $49,393 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$1.1M
- Regeneron$985K
- Genentech, Inc.$45K
- F. Hoffmann-la Roche AG$5K
What the payments were for
- Consulting fees$46,07867%
- Speaking & faculty fees$4,1256%
- Travel & lodging$14,46821%
- Food & beverage$1,6332%
- Education$2,0283%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| F. Hoffmann-la Roche AG | 6 | $24,313 |
| Regeneron | 8 | $13,734 |
| Astrazeneca UK Limited | 5 | $10,995 |
| Merck | 2 | $5,655 |
| Medtronic | 2 | $4,125 |
| AstraZeneca | 11 | $4,021 |
| Genentech USA, Inc. | 1 | $2,825 |
| Intuitive Surgical | 10 | $2,094 |
| Atricure, Inc. | 3 | $304 |
| Ambu Inc. | 1 | $125 |
| E.r. Squibb & Sons, L.L.C. | 1 | $60 |
| BD | 1 | $44 |
| Astrazeneca AB | 1 | $38 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TECENTRIQ$23,588
- Alecensa$20,763
- LIBTAYO$13,468
- DUPIXENT$5,915
- IMFINZI$5,044
- TAGRISSO$4,430
- Signia$2,625
- DAVINCI XI$1,000
- Da Vinci Surgical System$962
- ATRICURE CRYOICE CRYOSPHERE CRYOABLATION SYSTEM$229
How this compares
$68,333 in reported general payments places this provider in the 90th percentile of 383 thoracic surgery (cardiothoracic vascular surgery) providers in New York.
See all thoracic surgery (cardiothoracic vascular surgery) providers in New York →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other thoracic surgery (cardiothoracic vascular surgery) in New York
- Aubrey GallowayNew York$5.7M
- Gilbert TangNew York$842K
- Michael ZervosNew York$811K
- Elias ZiasNew York$465K
- Isaac GeorgeNew York$395K
- Eugene GrossiNew York$350K
- Costas BizekisNew York$321K
- Brendon StilesNew York$314K
- Daniela MolenaNew York$221K
- Arnar GeirssonNew York$218K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.